| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1054-3589(10)59008-2 |
| P8608 | Fatcat ID | release_2yrfdike4rgvroqkzwrdtrmzne |
| P698 | PubMed publication ID | 20933204 |
| P50 | author | Ingrid Fleming | Q21261982 |
| P2093 | author name string | Voahanginirina Randriamboavonjy | |
| P2860 | cites work | Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum | Q73436742 |
| Sphingosine-1-phosphate: characterization of its inhibition of platelet aggregation | Q74156419 | ||
| Significance of chemokines and activated platelets in patients with diabetes | Q74261220 | ||
| Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients | Q74303163 | ||
| Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus | Q77689859 | ||
| SNARE protein degradation upon platelet activation: calpain cleaves SNAP-23 | Q78696375 | ||
| Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis | Q80550892 | ||
| Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets | Q80730850 | ||
| Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway | Q81163093 | ||
| Identification of calpastatin and mu-calpain and studies of their association in pulmonary smooth muscle mitochondria | Q81296129 | ||
| Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion | Q83153688 | ||
| Advanced glycation end products strongly activate platelets | Q84295860 | ||
| beta-Actin regulates platelet nitric oxide synthase 3 activity through interaction with heat shock protein 90 | Q24305875 | ||
| Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway | Q24306460 | ||
| Calpain-mediated degradation of reversibly oxidized protein-tyrosine phosphatase 1B | Q24310309 | ||
| Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A | Q24314667 | ||
| Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis | Q28140458 | ||
| The calpain system | Q28185062 | ||
| Platelet-collagen interaction: is GPVI the central receptor? | Q28185377 | ||
| Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis | Q29547538 | ||
| PEST sequences and regulation by proteolysis | Q29616394 | ||
| Platelet adhesion to collagen under flow conditions in diabetes mellitus | Q30466038 | ||
| SNAP-23 is a target for calpain cleavage in activated platelets. | Q30711945 | ||
| Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen | Q32128376 | ||
| Platelet PECAM-1 inhibits thrombus formation in vivo. | Q33223436 | ||
| Calpain activation in experimental glaucoma | Q33526954 | ||
| Platelets and megakaryocytes contain functional nuclear factor-kappaB. | Q33782701 | ||
| Disruption of the mouse mu-calpain gene reveals an essential role in platelet function | Q33967742 | ||
| von Willebrand factor binding to platelet GpIb initiates signals for platelet activation | Q34208569 | ||
| Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain | Q34277120 | ||
| Calpain-10: from genome search to function. | Q34435033 | ||
| Signaling and regulation of the platelet glycoprotein Ib-IX-V complex | Q34616663 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| Chemokines in atherosclerosis: an update | Q34656531 | ||
| Role of calpain in adipocyte differentiation | Q34987400 | ||
| Glycoprotein Ib-IX-V. | Q35131686 | ||
| Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets | Q35950307 | ||
| Platelet GPIb-IX-V-dependent signaling | Q36230867 | ||
| Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. | Q36293675 | ||
| A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo | Q36370457 | ||
| Calpain activity in retinal degeneration. | Q36685247 | ||
| Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems | Q36766030 | ||
| Calpain-mediated regulation of platelet signaling pathways | Q36783478 | ||
| Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity | Q36803375 | ||
| Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. | Q36934868 | ||
| Unresolved roles of platelet nitric oxide synthase | Q36974994 | ||
| Platelet chemokines in vascular disease | Q37131719 | ||
| Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration | Q37237452 | ||
| Replication of calpain-10 genetic association with carotid intima-media thickness | Q37279026 | ||
| Inhibition of calpain blocks platelet secretion, aggregation, and spreading | Q37307187 | ||
| Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions | Q37428365 | ||
| PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways. | Q37470574 | ||
| Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation | Q37580452 | ||
| Mitochondrial calpain system: an overview | Q37662796 | ||
| New drug therapies for multiple sclerosis. | Q37736234 | ||
| Calmodulin-binding proteins as calpain substrates. | Q38308360 | ||
| A novel calpain inhibitor, ((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo | Q39775419 | ||
| Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta | Q40337760 | ||
| Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells | Q40633484 | ||
| Calpain: new perspectives in molecular diversity and physiological-pathological involvement. | Q40694801 | ||
| The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease | Q41173254 | ||
| Evidence for abnormal platelet glycoprotein expression in diabetes mellitus | Q41194133 | ||
| Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation | Q41928597 | ||
| Insulin stimulates the degradation of IRS-1 in 3T3-L1 adipocytes | Q41938340 | ||
| Insulin, insulin resistance, and platelet signaling in diabetes | Q41951212 | ||
| Activity profile of calpains I and II in chronically infarcted rat myocardium--influence of the calpain inhibitor CAL 9961. | Q41981503 | ||
| Sphingosine enhances platelet aggregation through an increase in phospholipase C activity by a protein kinase C-independent mechanism | Q42161692 | ||
| Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. | Q42453569 | ||
| Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest | Q43228745 | ||
| Sphingosylphosphorylcholine, a naturally occurring lipid mediator, inhibits human platelet function | Q43263531 | ||
| Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus | Q43541597 | ||
| Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. | Q43554882 | ||
| Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain | Q43576470 | ||
| Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. | Q43787195 | ||
| Antioxidant improves smooth muscle sarco/endoplasmic reticulum Ca(2+)-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation. | Q44011989 | ||
| Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus | Q44301386 | ||
| Glutamate substitutions at a PKA consensus site are consistent with inactivation of calpain by phosphorylation | Q44428909 | ||
| A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin | Q44449208 | ||
| Limb-girdle muscular dystrophy type 2A can result from accelerated autoproteolytic inactivation of calpain 3. | Q44612800 | ||
| NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity | Q44626143 | ||
| Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease | Q44938343 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide | Q45111036 | ||
| Cleavage of platelet endothelial cell adhesion molecule-1 (PECAM-1) in platelets exposed to high shear stress. | Q45154427 | ||
| Mean platelet volume in patients with type 2 diabetes mellitus | Q46374398 | ||
| At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products | Q46450292 | ||
| Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells | Q46552615 | ||
| Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia | Q46650194 | ||
| Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone | Q46856893 | ||
| Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease | Q46909923 | ||
| Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects | Q46926316 | ||
| Proteolytic cleavage of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is regulated by a calmodulin-binding motif | Q47344242 | ||
| Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients | Q47734969 | ||
| Increased aggregation of human platelets produced by advanced glycation end products in vitro | Q47799480 | ||
| Studies of high and low insulin responders with the hyperglycemic clamp technique. | Q52584321 | ||
| The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. | Q53424335 | ||
| Characteristics of mitochondrial calpains. | Q53538933 | ||
| Calpain-10 gene polymorphism is associated with reduced beta(3)-adrenoceptor function in human fat cells. | Q53965731 | ||
| RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. | Q54014329 | ||
| Impaired interaction of platelets with endothelial progenitor cells in patients with cardiovascular risk factors | Q58816191 | ||
| AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets | Q60760894 | ||
| Antithrombotic properties of vascular endothelium | Q66696852 | ||
| Effects of exercise and lack of exercise on insulin sensitivity and responsiveness | Q68149334 | ||
| Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation | Q71071086 | ||
| Effects of insulin on calcium metabolism and platelet aggregation | Q71258054 | ||
| Calcium influx is a determining factor of calpain activation and microparticle formation in platelets | Q71447635 | ||
| Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus | Q71781373 | ||
| Detection of platelet-derived microparticles in patients with diabetes | Q72541717 | ||
| Activation of human platelet protein kinase C-beta 2 in vivo in response to acute hyperglycemia | Q73041884 | ||
| P304 | page(s) | 235-257 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Advances in Pharmacology | Q15753809 |
| P1476 | title | The role of calpain in diabetes-associated platelet hyperactivation | |
| P478 | volume | 59 |
| Q50300963 | A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. |
| Q34204639 | Calpain activity and Toll-like receptor 4 expression in platelet regulate haemostatic situation in patients undergoing cardiac surgery and coagulation in mice. |
| Q37857282 | Calpain inhibitors: a survey of compounds reported in the patent and scientific literature |
| Q54450140 | Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. |
| Q46832266 | L-type calcium channel blocker ameliorates diabetic encephalopathy by modulating dysregulated calcium homeostasis |
| Q64268440 | Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy |
| Q42712249 | Targeting proteases in atherosclerosis: hitting the nail with the hammer |
| Q33413094 | The role of calpain-myosin 9-Rab7b pathway in mediating the expression of Toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking |
Search more.